Top

Published in:

01-07-2018 | Original Article

Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study

Authors: Jeevendra Kanagalingam, Mohamed Ibrahim A. Wahid, Jin-Ching Lin, Nonette A. Cupino, Edward Liu, Jin-Hyoung Kang, Shouki Bazarbashi, Nicole Bender Moreira, Harsha Arumugam, Stefan Mueller, Hanlim Moon

Published in: Supportive Care in Cancer | Issue 7/2018

Abstract

Purpose

This descriptive cross-sectional survey aims to assess the level of concordance between the perspectives of oncologists and those of patients regarding oral mucositis (OM) symptoms, and the impact of OM on various aspects of daily living and concurrent cancer management.

Methods

Oncologists involved in OM management (n = 105), and patients who developed OM during cancer treatment (n = 175), were recruited from seven Asian countries. Oncologists completed a face-to-face, quantitative interview; patients completed a face-to-face interview, and a self-reported questionnaire.

Results

Oncologists and patients ranked treatment-induced OM among the three most important toxicities of cancer therapy requiring intervention. The most frequent OM symptoms reported by patients were oral ulcers (74%), dry mouth (73%), and difficulty swallowing (62%). Oncologists expected mild OM symptoms to last slightly longer than 1 week, whereas patients reported mild symptoms for more than 2 weeks. In mild-to-moderate OM, oncologists underestimated patients’ pain experience. Overall, only 45% of oncologists said they would initiate OM prophylaxis when cancer therapy started. Of the 87% of patients who said they used their prescribed medications, only 16% reported using prophylactically prescribed medication. While oncologists’ concerns related to the delays and interruptions of cancer treatment, patients tended to focus on the effects of OM on eating, drinking, and talking.

Conclusions

Oncologists’ and patients’ perceptions about treatment-induced OM differ. To overcome discordant perspectives, there is a need to raise general awareness and improve proactive management of OM. As noted in recent guidelines, supportive cancer care is critical for ensuring optimal therapy and for improving the patient’s experience.

Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE (2015) Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2(4):202–211. https://doi.org/10.1007/s40496-015-0069-4 CrossRefPubMedPubMedCentral

Belgioia L, Bacigalupo A, Alterio D, Russi E, Corvo R (2015) Management of oropharyngeal mycosis in head and neck cancer occurring during (chemo) radiotherapy: an Italian radio-oncologist survey. Tumori 101(3):312–317. https://doi.org/10.5301/tj.5000284 CrossRefPubMed

Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM, 3rd (2008) NCCN Task Force Report. prevention and management of mucositis in cancer care Journal of the National Comprehensive Cancer Network : JNCCN 6 Suppl 1: S1–21

Borbasi S, Cameron K, Quested B, Olver I, Evans D (2002) More than a sore mouth: patients’ experience of oral mucositis. Oncol Nurs Forum 29:183–205CrossRef

Bossi P, Numico G, De Santis V, Ruo Redda MG, Reali A, Belgioia L, Cossu Rocca M, Orlandi E, Airoldi M, Bacigalupo A, Mazzer M, Saibene G, Russi E (2014) Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Support Care Cancer 22(7):1889–1896. https://doi.org/10.1007/s00520-014-2166-7 PubMedCrossRef

Cheng KK (2007) Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy. European journal of oncology nursing : the official journal of European Oncology Nursing Society 11(1):36–42. https://doi.org/10.1016/j.ejon.2006.03.004 CrossRef

Cheng KK, Leung SF, Liang RH, Tai JW, Yeung RM, Thompson DR (2010) Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life. Support Care Cancer 18(11):1477–1485. https://doi.org/10.1007/s00520-009-0771-7 CrossRefPubMed

Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS (2001) Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients European journal of cancer (Oxford, England) : 1990) 37: 2056–2063

De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendjik JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV (2016) Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol 100:147–166. https://doi.org/10.1016/j.critrevonc.2016.01.010 CrossRefPubMed

10.

Dein S (2004) Explanatory models of and attitudes towards cancer in different cultures. The Lancet Oncology 5(2):119–124. https://doi.org/10.1016/S1470-2045(04)01386-5 CrossRefPubMed

11.

Dodd MJ, Dibble S, Miaskowski C, Paul S, Cho M, MacPhail L, Greenspan D, Shiba G (2001) A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis. J Pain Symptom Manag 21(6):498–505. https://doi.org/10.1016/S0885-3924(01)00277-9 CrossRef

12.

Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-Llonch M, Burden of Illness H, Neck Writing C (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113(10):2704–2713. https://doi.org/10.1002/cncr.23898 CrossRefPubMed

13.

European Society for Opinion and Market Research (2008) ICC/ESOMAR Code on Market and Social Research. In: Editor (ed)^(eds) Book ICC/ESOMAR Code on Market and Social Research., City

14.

Farooqui M, Hassali MA, Shatar AK, Shafie AA, Seang TB, Farooqui MA (2011) A qualitative exploration of Malaysian cancer patients' perspectives on cancer and its treatment. BMC Public Health 11(1):525. https://doi.org/10.1186/1471-2458-11-525 CrossRefPubMedPubMedCentral

15.

Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(17):3485–3490. https://doi.org/10.1200/JCO.2004.03.025 CrossRef

16.

Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505–515. https://doi.org/10.1007/s00520-006-0055-4 CrossRefPubMed

17.

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831. https://doi.org/10.1002/cncr.22484 CrossRefPubMed

18.

Lai JS, Beaumont JL, Diaz J, Khan S, Cella D (2016) Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer 122(2):287–295. https://doi.org/10.1002/cncr.29655 CrossRefPubMed

19.

Lalla RV (2015) Alleviating mucositis: are we on track for a novel therapeutic? Expert Rev Gastroenterol Hepatol 9(2):127–128. https://doi.org/10.1586/17474124.2015.965146 CrossRefPubMed

20.

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer, International Society of Oral Oncology (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy Cancer 120: 1453–1461

21.

Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin N Am 52(1):61–77, viii. https://doi.org/10.1016/j.cden.2007.10.002 CrossRefPubMedPubMedCentral

22.

Merriam S, Muhamad M (2013) Roles traditional healers play in cancer treatment in Malaysia: implications for health promotion and education. Asian Pac J Cancer Prev 14(6):3593–3601. https://doi.org/10.7314/APJCP.2013.14.6.3593 CrossRefPubMed

23.

Peterson DE, Bensadoun RJ, Roila F (2011) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22 Suppl 6: vi78–84

24.

Sheikh I, Ogden J (1998) The role of knowledge and beliefs in help seeking behaviour for cancer: a quantitative and qualitative approach. Patient Educ Couns 35(1):35–42. https://doi.org/10.1016/S0738-3991(98)00081-0 CrossRefPubMed

25.

The College of Surgeons of England, The British Society for Disability and Oral Health (2012) The oral management of oncology patients requiring radiotherapy, chemotherapy and / or bone marrow transplantation. In: Editor (ed)^(eds) Book The oral management of oncology patients requiring radiotherapy, chemotherapy and / or bone marrow transplantation, City

26.

Tomlinson D, Gibson F, Treister N, Baggott C, Judd P, Hendershot E, Maloney AM, Doyle J, Feldman B, Kwong K, Sung L (2009) Understandability, content validity, and overall acceptability of the Children's International Mucositis Evaluation Scale (ChIMES): child and parent reporting. J Pediatr Hematol Oncol 31(6):416–423. https://doi.org/10.1097/MPH.0b013e31819c21ab CrossRefPubMed

27.

Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V, Costazza G, Mega A, Matozzo V, Berni M, Alberani F, Banfi MM, Martinelli L, Munaron S, Orlando L, Lubiato L, Leanza S, Guerrato R, Rossetti A, Messina M, Barzetti L, Satta G, Dimonte V (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT-results of a multicentre study. Bone Marrow Transplant 46(5):727–732. https://doi.org/10.1038/bmt.2010.184 CrossRefPubMed

28.

Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 15(5):491–496. https://doi.org/10.1007/s00520-006-0176-9 CrossRefPubMed

29.

Vera-Llonch M, Oster G, Hagiwara M, Sonis S (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106(2):329–336. https://doi.org/10.1002/cncr.21622 CrossRefPubMed

30.

Wygoda A, Maciejewski B, Skladowski K, Hutnik M, Pilecki B, Golen M, Rutkowski T (2009) Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys 73(2):384–390. https://doi.org/10.1016/j.ijrobp.2007.12.057 CrossRefPubMed

31.

Yavuz B, Bal Yilmaz H (2015) Investigation of the effects of planned mouth care education on the degree of oral mucositis in pediatric oncology patients. Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses 32(1):47–56. https://doi.org/10.1177/1043454214554011 CrossRef

32.

Zhu G, Lin JC, Kim SB, Bernier J, Agarwal JP, Vermorken JB, Thinh DH, Cheng HC, Yun HJ, Chitapanarux I, Lertsanguansinchai P, Reddy VA, He X (2016) Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer 16(1):42. https://doi.org/10.1186/s12885-016-2073-z CrossRefPubMedPubMedCentral

Title: Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study
Authors: Jeevendra Kanagalingam
Mohamed Ibrahim A. Wahid
Jin-Ching Lin
Nonette A. Cupino
Edward Liu
Jin-Hyoung Kang
Shouki Bazarbashi
Nicole Bender Moreira
Harsha Arumugam
Stefan Mueller
Hanlim Moon
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4050-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Sestrin family of genes and their role in cancer-related fatigue

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients

Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses

Ixazomib-induced cutaneous necrotizing vasculitis

Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers

Fertility information needs and concerns post-treatment contribute to lowered quality of life among young adult female cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer